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Abstract
Background: Motor neuron diseases (MND) are rare yet severe neu-
rodegenerative disorders with peculiar characteristics of unknown etio-
logies that cannot be prevented. They are irreversible and incurable, 
but treatable diseases. Treatment can improve the quality of life and 
increase survival. This study aimed to investigate the impact of epide-
miological and clinical factors in individuals with motor neuron disea-
ses, particularly amyotrophic lateral sclerosis (ALS). This study aimed 
to analyse the survival of patients with ALS in relation to clinical and 
epidemiological aspects.
Methods: Data were collected from charts in the Division of Clini-
cal Investigation on Neuromuscular Diseases (DCINM), (from 1999 to 
2011). Kaplan-Meier curves illustrated the survival time.
Results: A total of 1146 records of patients with MND were investi-
gated and 578 records, in accordance with the inclusion criteria, were 
included. For analyzing epidemiological and clinical aspects 231 records 
were included and survival curves were plotted. 
Conclusion: The survival of patients with MND was not influenced 
by sex. Younger patients live longer. Too much time passes between 
initial symptoms and 1st appointment. Patients who survive longest are 
those who were not diagnosed on the 1st appointment, or did not 
show any clinical and electromyographic findings, and presented with 
initial symptoms in the lower limbs.
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Introduction
The motor neuron diseases (MND) are a group of 
neurodegenerative disorders that predominantly 
affect the motor system. Among them include 
progressive muscular atrophy (PMA) that attacks 
lower motor neurons (LMN); progressive bulbar pal-
sy (PBP), which causes upper motor neuron (UMN) 
lesions as well as lower; primary lateral sclerosis 
(PLS), encompassing only UMN injury; and amyo-
trophic lateral sclerosis (ALS), which results from 
the combined degeneration of UMN and LMN [1, 
2].
Clinically characterized by weakness, hyperre-
flexia, and spasticity when there is involvement of 
the UMN and twitching, atrophy, weakness, and 
hyporeflexia when there is involvement of the LMN, 
MNDs are classified according to the site of primary 
involvement of motor neurons, the morphological 
changes, the inheritance pattern and electrophysio-
logical findings. Its evolution can compromise all 
members, including the bulbar muscles. The survival 
of patients with these disorders is low and may vary 
depending on the initial involvement of the neuro-
muscular system [3].
The epidemiological studies, clinical studies, and 
especially the experiments with animal models lead 
to the conclusion that ALS/MND disease is related 
to the presence of some genetic factor [4-5]. The 
clinical expression of symptoms could be related 
to a genetic predisposition in such patients, who 
have a genetic marker for some factor or factors 
that incites a cascade of neurotoxic activities, tri-
ggering the motor neuron degeneration process 
activated in special situations. Among the triggers, 
we highlight endogenous factors, such as inflam-
mation and mitochondrial, systemic or exogenous 
changes, such as exposure to toxic agents, stre-
nuous activities, and intake of food and medicine 
[4-16].
The diagnosis of ALS is currently related to the 
history and progression of the disease, with evi-
dence of the involvement of UMN and LMN [17], 
according to the criteria of EI Escorial [18]. To de-
termine the involvement of the LMN physicians use 
electromyography (EMG) that assesses the degree 
of impaired nerve conduction velocity in motor fi-
bers [19-20]. It is difficult, however, to detect the 
involvement of UMN, as there are often only mild 
impairment signals, which can generate questions 
for the definitive diagnosis of ALS and the need to 
rule out other diseases [17, 20-22].
There is interest in understanding pathophysio-
logy of ALS/MND. Research conducted in recent 
years has shown that ALS/MND is not a disease 
with a single cause. There are no doubts that ALS/
MND is clinically and biologically a heterogeneous 
neurological disorder. The recognition of this hete-
rogeneity is important, especially when proposing 
to carry out clinical trials, which may not work for 
most, but can help some patients. This opens a 
rare opportunity to target etiopathogenic aspects 
of the disease, seeking therapeutic interventions 
that can increase patient survival rates. Today, we 
seek not just to know more about the causes of 
these diseases but also what can be used as a 
protective factor [23].
Objective 
To analyze the survival of patients with amyotro-
phic lateral sclerosis/ motor neuron diseases (ALS/
MND) in relation to clinical and epidemiological 
aspects.
Methods
This is a prospective cohort study. It has been ap-
proved by the Ethics Comittee of Federal University 
of São Paulo. During the 12-year study-period (from 
1999-2011), we identified patients from the Motor 
Neuron Disease Clinic from the Division of Clinical 
Investigation on Neuromuscular Diseases (DCINM) 
[24], Department of Neurology and Neurosurgery 
of the Federal University of São Paulo. These pa-
tients had received an ALS diagnosis, according to 
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the criteria of El Escorial from the World Federation 
of Neurology (World Federation of Neurology Re-
search Group on Neuromuscular Diseases).
The 1146 patients with MND were analyzed. Al-
most half, or 568 (49.56%) patient records were 
excluded because they had not received a definite 
diagnosis of ALS/MND or they were incomplete be-
cause either the patient had been in the process of 
assessment and the record did not contain all requi-
red information or certain questions had not been 
answered by the patient or their primary caregiver. 
We included all 578 (50.43%) records that contai-
ned the confirmed diagnosis of ALS/MND according 
to revised criteria of El Escorial World Federation of 
Neurology [25]. The tabulated data records for the 
analysis of the study were taken from a total of 231 
patients who had died, featuring
•   epidemiological aspects: age, sex, and skin color
•   pathophysiological  symptoms:  classification 
and form of MND
•   clinical  aspects:  time  of  diagnosis,  whether 
the diagnosis had been made before or after 
the first visit to the DCINM, the initial topo-
graphy of clinical impairment, and the presen-
ce of electromyography in first appointment 
in DCINM
•   therapeutic  aspects,  such  as  pre-consultation 
time: time between the initial symptom of di-
sease until the 1st. DCINM appointment
•   diagnostic  time: period of  time  from  the first 
appointment date at DCINM until diagnosis
•   dwell  time:  the  time  period  from  the  first 
DCINM appointment until death
•   death: time from diagnosis until death
•   total  duration of  the disease:  symptom onset 
time to death.
Statistical Analysis
The semi-continuous and continuous data were ini-
tially compared to the Gaussian curve by the KS dis-
tance and when a nonparametric test were repre-
sented by the median and percentiles and compared 
with results from a Mann-Whitney test. Categorical 
data were represented by absolute frequency (n) 
and relative frequency (%).
Survival analysis was performed using the Ka-
plan-Meier model and the estimated median values 
if survival was followed by the standard error of 
estimate. Comparisons between the survival cur-
ves were performed by the log-rank test. For all 
statistical comparisons, we considered the level of 
significance of 5%. Statistical tests were performed 
using SPSS 19.0 IBM Corporation.
Results
For survival analysis, we considered the records of 
231 patients who had died during the 12-year study 
period. The median overall survival period was 10.3 
± 0.71 months; we set the lower confidence interval 
(CI) of 95% at 9.0 months and an upper CI of 95% 
at 11.7 months.
In the overall survival curve, we identified that 
the majority (144 patients) had died before 9 
months after their definitive diagnosis, while 87 
patients survived beyond 9 months after definitive 
diagnosis. Considering the lower CI 95% we de-
fined two phases of survival analysis: < 9 months 
and > 9 months.
We defined  those with  survival < 9 months as 
patients with early mortality or with shorter sur-
vival and those with mortality ≥ 9 months with 
longer survival; therefore, we could establish what 
factors could be related to the determination of 
greater or lesser expectation of life in both groups 
(Figure 1).
Regarding the epidemiological characteristics of 
the deceased patients (n = 231), the median age of 
the patients analysed < 9 months was 63 and ≥ 9 
months was 57 years (p < 0.05). Males prevailed in 
56.1% (131 patients); the ratio of men to women 
was 1.32:1 (p = 0.001) (Table 1). As for the color of 
the skin we found that the white color was most 
common, accounting for 90% (209 patients), fo-
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llowed by the black color in 9% (19 patients) and 
1% of asian patients (3 patients).
As for MND rating, ALS was the most pre-
valent (73.6%) cases, followed by PBP (21.2%), 
PMA (4.3%) and PLA (0.9%) (Table 2). Sporadic 
clinical presentation was found in 100% of cases. 
(Table 3)
In clinical aspects, patients receiving their diag-
nosis after the first visit had a higher survival time 
(21.1 months), compared to 17.4 months of pa-
tients diagnosed before the first appointment and 
13.7 months, of patients diagnosed at the first 
appointment (Table 4).
As for the correlation with the initial topogra-
phy of clinical impairment, we observed that the 
deceased patients who had initial impairment in 
the lower limbs had longer survival (19.9 months) 
than those who had initial involvement in the 
upper limbs (15.6 months) or bulbar region (14.7 
months). We observed also that patients who had 
initial involvement in the upper limbs did not have 
longer survival than those with bulbar involvement 
(Figure 2). 
Figure 1:  Survival curve of patients with amyotro-
phic lateral sclerosis/motor neuron disea-
se (ALS/MND) in time < 9 months and ≥ 
9 months.
Table 1.  Kaplan-Meier curve in patients with survival 
< and ≥ 9 months regarding time compa-
red by gender.








Female 63 4.1 0.74 2.66 5.54
0.524Male 81 4.3 0.29 3.74 4.86
General 144 4.2 0.25 3.71 4.7
≥ 9 
months
Female 41 15.6 2.18 11.33 19.87
0.241Male 46 15.3 1.41 12.53 18.07
General 87 15.6 1.24 13.16 18.04
SEM (standard error of mean)
Table 4.  Kaplan-Meier curve in patients with ≥ sur-
vival to 9 months as the time of diagnosis.
Time diagnosis Median EPM ICI 95% ICS 95%
Before the 1st 
Consultation 
17.4 1.70 14.06 20.74
The 1st 
Consultation
13.7 0.44 12.84 14.56
After the 1st 
Consultation 
21.1* 0.20 20.71 21.49
General 15.60 1.24 13.16 18.04
* p <0.05 vs 1 in the query ; - Log Rank test
Table 2.  Classification of Motor Neuron Diseases 
(MND).






Table 3. Types of Motor Neuron Diseases (MND).
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The correlation with electromyography revealed 
that seven patients had not been submitted to this 
methodology before the first visit to the DCINM and 
these had a higher survival rate than those who had 
previously undergone the examination, both with 
compatible diagnosis of ALS (15.9 months) and tho-
se whose as diagnosis did not mention ALS (14.7 
months). Table 5 shows representative data on sur-
vival time ≥ than 9 months.
Discussion
For survival analysis, we assessed the medical re-
cords of 231 patients, who died in the follow-up 
period of this study. For the deceased who passed 
away before 9 months elapsed after their diagnostic 
confirmation, the median age was 63 years, while 
the median age of the deceased who passed away 
at the time greater than or equal to 9 months from 
diagnosis was 57 years old; however, it was not 
possible to make analysis of survival. However, a re-
trospective study with 135 patients with ALS/MND 
in Scotland, describes a difference between young 
and elderly patients, demonstrating differences in 
the clinical presentation, survival, and in the process 
of care [26].
In a mortality study conducted in the city of São 
Paulo from 2002 to 2006, data on 158 men and 
168 women showed no difference between the se-
xes [27]. However, another study found 127 male 
patients (56%) and 104 (44%) females with a pre-
dominance of males, which is in agreement with 
the Brazilian literature. This fact can be explained 
by the retrospective time difference studied and 
causality [28-32].
Regarding skin color, skin was predominantly 
white in color in the deceased group (90%). In the 
work of Matos et al. [27], Dietrich-Neto et al. [29] 
Figure 2:  Kaplan-Meier curve in patients with survival < and ≥ to nine months as the topography.
Table 5.  Kaplan-Meier curve in patients with ≥ sur-
vival than 9 months measuring electromyo-
graphy before the first appointment.
Electromyography Median EPM ICI 95% ICS 95%
Not done 18.4 . . .
Compatible 
diagnosis of ALS
15.9* 1.26 13.42 18.38
Diagnosis not 
referred to as ALS
14.7 1.22 12.32 17.08
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follows the predominant order of white skin color 
as referred to in this study. Also data from the State 
System Foundation Data Analysis (SEADE 2004) [33] 
showed that more than half of the racial composi-
tion of the city and metropolitan area of São Paulo 
is white [33].
Regarding the classification of the disease, Pa-
tients with ALS represented 73.6%; this finding is 
due justification, of the total number of cases of 
patients with MND, ALS was the most represented 
(74%). The sporadic form was recognized in 100% 
of deceased patient cases. The rationale is similar 
to the previous one:  looking at the total number 
of cases of patients with MND, sporadic appears 
in 95% of cases. These data are described in the 
clinical study of patients with MND at UNIFESP 
[25].
The median survival in clinical trials strongly de-
pends on the characteristics of the population and 
the inclusion criteria and related exclusions. Because 
of the many factors that can impact survival, further 
studies, with epidemiological investigations should 
be performed, with more homogeneous samples 
and factors, to comparatively analyse different cli-
nical trials. To avoid registration of subjective data, 
we consider the time from the date of the defined 
diagnosis of ALS/MND until the date of death for 
survival analysis.
Survival analysis, performed using the Kaplan-
Meier curve, enabled us to verify two different 
time  periods:  the  occurance  of  death  in  less 
than nine months time and death occurring at 9 
months or beyond and found a greater number 
of patients who died (144) in the period of less 
than 9 months.
Even as the DCINM is a referral center for the care 
of patients with ALS/MND, many patients evaluated 
for the first time in DCINM already had very advan-
ced clinical impairment. There was a delay, conside-
red too great between the first symptom and the 
patient’s first query at DCINM, ranging from 9 to 26 
months, with a median of 16 months. The delay of 
diagnosis and the most severe impairment, perhaps, 
justifies the lowest survival time in this population. 
Clinical studies [23,32] have shown that survival is 
lower in patients with major neuromuscular invol-
vement.
In the survival analysis of 231 patients related to 
gender, there was no significant difference between 
men and women, but the correlation of survival 
with age is not demonstrated in this study because 
it was not possible to set a cut-off point that could 
define higher or lower risk of death. 
Regarding the general monitoring time and sur-
vival in months for all patients who died, the sta-
tistical difference was related to duration of the 
disease, which was defined by the date of initial 
symptoms until the date of death and survival time, 
referring to the date of diagnosis until the date of 
death. If both measured longer than nine months, 
this implies that the patient who died after nine 
months shows an early condition for the diagnosis 
of the disease.
Regarding the correlation of survival with the 
time of diagnosis, there was greater survival di-
fference for patients diagnosed after the first visit 
to the DCINM, this may have occurred because 
patients who were not diagnosed during their first 
visit had a clinical commitment that was mild or 
less widespread and, therefore, were still under 
investigation.
As for survival related to the topography of the 
start of the first symptom, patients presenting with 
appendicular initial impairment had longer survival, 
especially those who started with symptoms in the 
lower limbs. It is believed that the occurring motor 
neuron involvement affects the proximal cells with 
a degenerative impairment. Being a disease where 
there is a spread of clinical manifestations in a con-
tiguous manner, there is a greater time commitment 
to spinal and bulbar structures that are more related 
to vital functions (breathing, swallowing), when the 
initial manifestations are due to lumbosacral ma-
rrow involvement [23, 34-36].
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We did a survival analysis using the presence or 
absence of the subsidiary electromyography test 
(EMG) given at the first visit to the DCINM. Pa-
tients who had not been tested before the first 
appointment had longer survival than those with 
compatible exams and who were not compatible 
with a diagnosis of ALS/MND. It can be inferred 
that this finding is related to the lower neuromotor 
impairment of these cases and, therefore, doctors 
who were visited prior to the medical appointment 
in DCINM, were not considered relevant request 
ENMG in these cases.
Conclusions
As for patient survival analysis with ALS/ MND, we 
find the time period between initial symptoms and 
the first appointment is too long. There was no 
significant difference in survival between the sexes.
Long-term survival is associated with younger 
patients who had no diagnosis defined in the first 
appointment and who did not present with clini-
cal signs electromyography diagnostics, or onset of 
symptoms in the lower limbs.
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